10x Genomics Inc. recently held a conference call to discuss its financial results for the first quarter ended June 30, 2025. The call was attended by CEO and Co-Founder Serge Saxonov, Chief Financial Officer Adam Taich, and Senior Director, Head of Investor Relations and Strategic Finance, Cassie Corneau. During the call, management highlighted the company's advancements and strategic initiatives. Notably, they discussed the use of their Chromium Universal 5' assay by Xaira Therapeutics to produce the largest publicly-available, genome-wide Perturb-seq dataset to date. Furthermore, 10x Genomics announced the extension of its partnership with the Arc Institute to support the Virtual Cell Challenge, which aims to develop computational models of biology. Management emphasized the importance of understanding cells to advance health and disease research, stating, "If we can model cells and perturbations computationally using AI, we can guide the discovery of new drugs." Additionally, they announced the acquisition of Scale Biosciences to accelerate innovation across their Chromium platform. The full transcript can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.